Are very low LDL-c levels safe?
Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients
Video navigation menu
- Are very low LDL-c levels safe and desirable in the current therapeutic climate? 00:22
- Are there any problems with biological functions with very low LDL-c levels? 01:35
- Is there any reason for fears about neurological problems with low LDL-c levels? 03:20
- The benefit/risk ratio of new therapies 05:31
This video was recorded during an expert meeting among cardiologists and internists, focussing on the topic of 'LDL-c & PCSK9 inhibition in high CV risk patients - Balancing Science, Guidelines and Daily Cardiology Practice'.
The objectives of the meeting were to:
- Review recent outcome data with PCSK9 inhibitors in the clinical management of patients who had a recent MI
- Discuss the importance of reaching LDL-c targets in patients post MI
- Provide a European expert perspective on the current challenges of reaching LDL-c targets and use of PCSK9 inhibitors in clinical cardiology
- Define key challenges, needs and goals for education to ensure the implications of new outcome trials like FOURIER and ODYSSEY-outcomes will be adopted in post MI patients
- Develop a consensus and clinical guidance on lowering LDL-c in post MI patients
Other topics covered in this series
Other lectures part of this educational series are:
- LDL-c as target in cardiology: The road towards lower targets - Prof. John Kastelein, MD, Amsterdam, The Netherlands, & Prof. Chris Packard, MD, Glasgow, Scotland, UK
- The guidelines in need of a major change? - Prof. Kausik Ray, MD, London, UK, & Prof. François Mach, MD, Geneva, Switzerland
- What are the key issues and challenges impacting clinical management with novel therapeutics? - Prof. Kausik Ray, MD, London, UK, & Prof. Gilles Montalescot, MD, Paris, France
- Progressive CAD despite low LDL-c an elusive disease - Prof. Kausik Ray, MD, London, UK, & Prof. Wouter Jukema, MD, Leiden, The Netherlands
- How are the guidelines for progressive CAD guiding us in clinical practice? - Prof. John Kastelein, MD, Amsterdam, The Netherlands, & Prof. Ulf Landmesser, MD, Berlin, Germany
- FH in clinical cardiology: highly prevalent. Challenges for screening and treatment of FH patients - Prof. Kausik Ray, MD, London, UK, & Prof. Kees Hovingh, MD, Amsterdam, The Netherlands
Prof. John J.P Kastelein, internist, Amsterdam University Medical Centers, The Netherlands
Prof. Lluis Masana, internist, University Rovira and Virgili, Reus-Tarragona, Spain
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.
Funding for the Expert Meeting was provided by an unrestricted educational grant from Amgen. The sponsor did not attend and influence the video recording.
This is available as accredited online CME for members. Click the button below to enroll:Enroll